Renalytix Plc Financials
This page shows Renalytix Plc (RNLXY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Renalytix is operating like a cash-funded development company, with commercial revenue still far too small to absorb even reduced costs.
From FY2023 to FY2024, losses narrowed mainly because spending was cut: SG&A plus R&D fell by$13.9M . That improvement did not reflect a stronger sales engine, because revenue fell to$2.3M and gross margin compressed to6.8% , showing cash preservation outran commercialization.
In FY2024, operating cash burn was
The balance sheet crossed into negative equity, moving from
Financial Health Signals
We are recalculating Renalytix Plc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Renalytix Plc scores -34.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($415.2M) relative to total liabilities ($15.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Renalytix Plc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Renalytix Plc generates $0.90 in operating cash flow (-$30.1M OCF vs -$33.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Renalytix Plc generated $2.3M in revenue in fiscal year 2024. This represents a decrease of 32.7% from the prior year.
Renalytix Plc's EBITDA was -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.9% from the prior year.
Renalytix Plc reported -$33.5M in net income in fiscal year 2024. This represents an increase of 26.6% from the prior year.
Renalytix Plc earned $-0.31 per diluted share (EPS) in fiscal year 2024. This represents an increase of 43.6% from the prior year.
Cash & Balance Sheet
Renalytix Plc held $4.7M in cash against $0 in long-term debt as of fiscal year 2024.
Renalytix Plc had 154M shares outstanding in fiscal year 2024. This represents an increase of 64.6% from the prior year.
Margins & Returns
Renalytix Plc's gross margin was 6.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 14.3 percentage points from the prior year.
Renalytix Plc's operating margin was -1293.5% in fiscal year 2024, reflecting core business profitability. This is down 52.8 percentage points from the prior year.
Renalytix Plc's net profit margin was -1461.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 121.4 percentage points from the prior year.
Capital Allocation
Renalytix Plc invested $9.3M in research and development in fiscal year 2024. This represents a decrease of 35.0% from the prior year.
RNLXY Income Statement
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $522K-10.9% | $586K+9.5% | $535K-24.5% | $709K+54.5% | $459K-11.4% | $518K-28.5% | $724K-39.3% | $1.2M |
| Cost of Revenue | $422K-23.3% | $550K-8.5% | $601K+25.2% | $480K-4.4% | $502K-25.4% | $673K+11.6% | $603K-15.2% | $711K |
| Gross Profit | $100K+177.8% | $36K+154.5% | -$66K-128.8% | $229K+632.6% | -$43K+72.3% | -$155K-228.1% | $121K-74.8% | $481K |
| R&D Expenses | $921K-13.3% | $1.1M-52.1% | $2.2M-31.3% | $3.2M+15.7% | $2.8M-14.8% | $3.3M-17.0% | $3.9M+18.6% | $3.3M |
| SG&A Expenses | $3.3M-27.3% | $4.5M+16.7% | $3.9M-27.8% | $5.3M-11.9% | $6.1M-6.9% | $6.5M-8.3% | $7.1M+4.2% | $6.8M |
| Operating Income | -$4.1M+25.9% | -$5.5M+15.7% | -$6.6M+24.2% | -$8.6M+2.8% | -$8.9M+10.5% | -$9.9M+9.0% | -$10.9M-13.2% | -$9.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $2K | $0 | $0-100.0% | $4K | $0-100.0% | $2K+300.0% | -$1K | $0 |
| Net Income | -$4.7M+33.2% | -$7.1M+8.6% | -$7.7M+8.7% | -$8.5M+16.4% | -$10.2M+8.6% | -$11.1M+8.3% | -$12.1M-15.9% | -$10.4M |
| EPS (Diluted) | $-0.04 | N/A | $-0.08+11.1% | $-0.09+18.2% | $-0.11 | N/A | $-0.140.0% | $-0.14 |
RNLXY Balance Sheet
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.8M-39.9% | $8.0M-9.1% | $8.8M-22.2% | $11.3M-42.3% | $19.5M-36.2% | $30.6M-23.0% | $39.8M+29.8% | $30.7M |
| Current Assets | $2.9M-52.9% | $6.1M-3.5% | $6.3M-23.2% | $8.3M-49.9% | $16.5M-38.7% | $26.9M-24.8% | $35.7M+34.3% | $26.6M |
| Cash & Equivalents | $909K-80.6% | $4.7M-0.5% | $4.7M-16.3% | $5.6M-59.5% | $13.9M-43.7% | $24.7M-25.3% | $33.0M+38.7% | $23.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $902K+24.9% | $722K+30.3% | $554K-59.6% | $1.4M+35.1% | $1.0M+30.7% | $776K+3.9% | $747K-8.9% | $820K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.1M+1.8% | $15.8M-20.4% | $19.9M+3.4% | $19.2M-8.6% | $21.0M-11.1% | $23.7M+9.0% | $21.7M-0.3% | $21.8M |
| Current Liabilities | $12.0M+4.5% | $11.5M-23.3% | $15.0M+7.7% | $13.9M-8.2% | $15.2M-6.0% | $16.1M+9.9% | $14.7M+2.8% | $14.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$11.3M-44.1% | -$7.9M+29.3% | -$11.1M-39.7% | -$8.0M-433.6% | -$1.5M-121.4% | $7.0M-61.5% | $18.1M+103.7% | $8.9M |
| Retained Earnings | -$216.5M-2.2% | -$211.8M-3.5% | -$204.7M-3.9% | -$197.0M-4.5% | -$188.5M-5.7% | -$178.3M-6.6% | -$167.2M-7.8% | -$155.1M |
RNLXY Cash Flow Statement
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M+51.0% | -$7.8M-61.0% | -$4.9M+38.6% | -$7.9M+16.7% | -$9.5M-10.1% | -$8.6M+14.5% | -$10.1M-22.7% | -$8.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$8.6M+14.5% | -$10.1M-22.7% | -$8.2M |
| Investing Cash Flow | $23K+2400.0% | -$1K+66.7% | -$3K | $0 | $0-100.0% | $59K+1080.0% | $5K+107.8% | -$64K |
| Financing Cash Flow | $0-100.0% | $7.8M+93.1% | $4.0M+895.5% | -$507K+52.4% | -$1.1M-986.7% | -$98K-100.5% | $18.0M+3163.9% | -$588K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RNLXY Financial Ratios
| Metric | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.2%+13.0pp | 6.1%+18.5pp | -12.3%-44.6pp | 32.3%+41.7pp | -9.4%+20.6pp | -29.9%-46.6pp | 16.7%-23.6pp | 40.4% |
| Operating Margin | -784.1%+158.7pp | -942.8%+282.0pp | -1224.9%-6.1pp | -1218.8%+717.8pp | -1936.6%-18.8pp | -1917.8%-409.9pp | -1507.9%-698.5pp | -809.4% |
| Net Margin | -905.7%+301.4pp | -1207.2%+240.1pp | -1447.3%-250.5pp | -1196.8%+1015.4pp | -2212.2%-68.6pp | -2143.6%-471.5pp | -1672.1%-795.9pp | -876.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -159.4%-92.5pp | -66.9%+50.6pp | -117.5% |
| Return on Assets | -98.6%-9.9pp | -88.7%-0.4pp | -88.3%-13.1pp | -75.3%-23.3pp | -52.0%-15.7pp | -36.3%-5.8pp | -30.4%+3.6pp | -34.1% |
| Current Ratio | 0.24-0.3 | 0.53+0.1 | 0.42-0.2 | 0.59-0.5 | 1.09-0.6 | 1.67-0.8 | 2.43+0.6 | 1.86 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 3.40+2.2 | 1.20-1.3 | 2.45 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -1666.6%-271.4pp | -1395.2%-704.6pp | -690.6% |
Note: Shareholder equity is negative (-$7.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Renalytix Plc's annual revenue?
Renalytix Plc (RNLXY) reported $2.3M in total revenue for fiscal year 2024. This represents a -32.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Renalytix Plc's revenue growing?
Renalytix Plc (RNLXY) revenue declined by 32.7% year-over-year, from $3.4M to $2.3M in fiscal year 2024.
Is Renalytix Plc profitable?
No, Renalytix Plc (RNLXY) reported a net income of -$33.5M in fiscal year 2024, with a net profit margin of -1461.6%.
What is Renalytix Plc's EBITDA?
Renalytix Plc (RNLXY) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Renalytix Plc's gross margin?
Renalytix Plc (RNLXY) had a gross margin of 6.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Renalytix Plc's operating margin?
Renalytix Plc (RNLXY) had an operating margin of -1293.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Renalytix Plc's net profit margin?
Renalytix Plc (RNLXY) had a net profit margin of -1461.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Renalytix Plc's operating cash flow?
Renalytix Plc (RNLXY) generated -$30.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Renalytix Plc's total assets?
Renalytix Plc (RNLXY) had $8.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Renalytix Plc spend on research and development?
Renalytix Plc (RNLXY) invested $9.3M in research and development during fiscal year 2024.
What is Renalytix Plc's current ratio?
Renalytix Plc (RNLXY) had a current ratio of 0.53 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Renalytix Plc's return on assets (ROA)?
Renalytix Plc (RNLXY) had a return on assets of -419.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Renalytix Plc's cash runway?
Based on fiscal year 2024 data, Renalytix Plc (RNLXY) had $4.7M in cash against an annual operating cash burn of $30.1M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Renalytix Plc's debt-to-equity ratio negative or not reported?
Renalytix Plc (RNLXY) has negative shareholder equity of -$7.9M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Renalytix Plc's Altman Z-Score?
Renalytix Plc (RNLXY) has an Altman Z-Score of -34.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Renalytix Plc's Piotroski F-Score?
Renalytix Plc (RNLXY) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Renalytix Plc's earnings high quality?
Renalytix Plc (RNLXY) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.